← All trials
NCT04683796
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Mar 30, 2023
- First posted
- Dec 24, 2020
- Last posted
- Feb 25, 2021
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mahidol UniversityLead sponsor
- Mahidol UniversityReponsible party - principal investigator
- Mahidol UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.